Nashua Dialysis is a medicare approved dialysis facility center in Nashua, New Hampshire and it has 22 dialysis stations. It is located in Hillsborough county at 38 Tyler Street, Nashua, NH, 03061. You can reach out to the office of Nashua Dialysis at (603) 598-1665. This dialysis clinic is managed and/or owned by Davita. Nashua Dialysis has the following ownership type - Profit. It was first certified by medicare in February, 2002. The medicare id for this facility is 302507 and it accepts patients under medicare ESRD program.
| Name | Nashua Dialysis |
|---|---|
| Location | 38 Tyler Street, Nashua, New Hampshire |
| No. of Dialysis Stations | 22 |
| Medicare ID | 302507 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 38 Tyler Street, Nashua, New Hampshire, 03061 | |
| (603) 598-1665 | |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
| NPI Number | 1700848819 |
| Organization Name | Nashua Dialysis |
| Doing Business As | Dva Renal Healthcare Inc |
| Address | 38 Tyler St Nashua, New Hampshire, 03060 |
| Phone Number | (603) 598-1665 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 64% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 20% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 16% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 14% |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 60% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 23% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 17% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 82% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 18% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 76 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 26 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 112 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 960 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 25 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 204 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 87 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Nashua Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 147 |
| Hypercalcemia patient months | 1274 |
| Patients with Serumphosphor | 149 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 34 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 112 |
| Patient months included in arterial venous fistula and catheter summaries | 897 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 80 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 114 |
| Hospitalization Rate in facility | 189 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 302.4 |
| Hospitalization Rate: Lower Confidence Limit | 126.9 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Nashua Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 16.7 (Better than Expected) |
| Readmission Rate: Upper Confidence Limit | 23.4 |
| Readmission Rate: Lower Confidence Limit | 11.3 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Nashua Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .58 (As Expected) |
| SIR: Upper Confidence Limit | 1.57 |
| SIR: Lower Confidence Limit | .15 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Nashua Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 98 |
| Transfusion Rate in facility | 30.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 69.6 |
| Transfusion Rate: Lower Confidence Limit | 15.2 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Nashua Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 606 |
| Mortality Rate in facility | 15.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19.8 |
| Mortality Rate: Lower Confidence Limit | 12.6 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago
Bio-Medical Applications Of New Hampshire, Inc. Location: 20 Cotton Road, Nashua, New Hampshire, 03063 Phone: (603) 577-4547 |
News Archive
A new technology harnesses imperfections that typically compromise MRI exams to create images resolved enough to enable consistent diagnoses across populations for the first time.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
In collaborative research, scientists from three continents were able to discover a crucial bit of information about how T cells move proteins inside them to drive the immune response. This could help evolve specific new treatments centered on T cell selectivity.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.
New findings from a Dartmouth Medical School collaboration in Tanzania may alter assumptions about the diagnosis of tuberculosis in HIV-infected people, and prompt a major change in way TB testing is routinely done in the developing world.
› Verified 4 days ago